상세 보기
품질경영학회지
ISSN
P 1229-1889 E 2287-9005
출판사
한국품질경영학회
국가
SOUTH KOREA
발행 상태
비활성
데이터베이스 수록 정보
KCI 2009-2025 (17년)
KCI 등재 2002-2026 (25년)
KCI 등재후보 1999-2001 (3년)
전체 5건 중 1번부터 5번까지의 결과를 표시합니다.
2026
Article
A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24)
- Kim, Miso ;
- Youk, Jeonghwan ;
- Kim, Tae Min ;
- Lee, Gyeong-Won ;
- Kim, Dong-Wan ;
- 외 1명
- 2026-04
- Clinical Lung Cancer
- Cancer Information Group
2025
Article
Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea
- Ahn, June Hong ;
- Choi, Sun Ha ;
- Park, Sun Hyo ;
- Kim, Insu ;
- Park, Jin Han ;
- ... Kim, Tae Hoon ;
- ... Jeong, Jong Hwan ;
- ... Yang, Jung Wook ;
- 외 11명
- 2025-06
- Clinical Lung Cancer
- Cancer Information Group
2024
Article
Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study
- Park, Ji Eun ;
- Hong, Kyung Soo ;
- Choi, Sun Ha ;
- Lee, Shin Yup ;
- Shin, Kyeong-Cheol ;
- 외 13명
- 2024-06
- Clinical Lung Cancer
- Cancer Information Group
2022
Article
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
- Kim, K.H. ;
- Yoon, S. ;
- Ahn, H.K. ;
- Lee, S.Y. ;
- Lee, G.-W. ;
- 외 5명
- 2022-12
- Clinical Lung Cancer
- Elsevier Inc.
2020
Article
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
- Senan, Suresh ;
- Okamoto, Isamu ;
- Lee, Gyeong-Won ;
- Chen, Yuanbin ;
- Niho, Seiji ;
- 외 5명
- 2020-03
- Clinical Lung Cancer
- CIG MEDIA GROUP, LP